Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kymera Therapeutics, Inc.

26.36
+1.134.46%
Post-market: 26.06-0.3000-1.14%19:22 EDT
Volume:717.14K
Turnover:18.80M
Market Cap:1.71B
PE:-8.84
High:26.79
Open:24.81
Low:24.43
Close:25.24
Loading ...

Company Profile

Company Name:
Kymera Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
188
Office Location:
200 Arsenal Yards Boulevard,Suite 230,Watertown,Massachusetts,United States
Zip Code:
02472
Fax:
- -
Introduction:
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Directors

Name
Position
Bruce Booth
Founder, Chairman and Director
Nello Mainolfi
Founder, President, Chief Executive Officer and Director
Andrew Hedin
Director
Donald W. Nicholson
Director
Gorjan Hrustanovic
Director
Jeffrey Albers
Director
Joanna Horobin
Director
Steven Hall
Director

Shareholders

Name
Position
Nello Mainolfi
Founder, President, Chief Executive Officer and Director
Bruce Jacobs
Chief Financial Officer
Bruce Booth
Founder, Chairman and Director
Jared Gollob
Chief Medical Officer
Richard Chesworth
Chief Scientific Officer